IMGN could easily see prices not seen in ten years on the announcement that Roche/Genentech have filed the BLA for T-DM1 approval. It's very possible that the filing's actually already occurred, but this time they're playing it causious and waiting for FDA acceptance to announce it.
While I'm uncertain, I believe FDA acceptance may be a milestone with another to follow on FDA approval. After that it's all about reaching sales goals for further milestones, and royalties. As I see it, until it happens we'll not learn how IMGN receives it's royalty payments, i.e. does the money get paid to them monthly, quarterly, or just once annually. While the specific mode of payment matters little in the long term, initially shareholders will be chomping at the bit to learn what IMGN's earning, if it should be an annual event, people may be frustrated by the lack of information.
We may see $16 again today, just pennies away right now, it would be nice to see a close above $16.
Gary |
